Please note: The information displayed on this page might be outdated.
Atomwise: Operator of an artificial intelligence-based biotechnology company intended to help invent new potential medicines for more than 50 disease targets. The company's technology helps in drug hit discovery, binding affinity prediction and toxicity detection, enabling scientists to discover small molecules for the treatment and investigation of human diseases.
US - Pacific
San Francisco, CA
Company Participants at Winter Private Company Showcase
Atomwise, Co-Founder & CEO
Dr. Abraham Heifets is a Co-Founder and serves as Chief Executive Officer at Atomwise. He is an expert in big data and high-performance computing. He serves as Board Member at X-37. After completing his B.Sc. and M.E in Computer Science at Cornell, Abraham worked on high-performance computing at IBM's T.J. Watson Research Center. As a doctoral candidate at the University of Toronto, he created SCRIPDB, one of the largest public databases of patented chemical structures, and LigAlign, a protein analysis tool used by researchers in 70 countries. He was also named a fellow of Massey College and the Ontario Brain Institute.
Atomwise, Head of Operations